» Articles » PMID: 33477465

From Posttranslational Modifications to Disease Phenotype: A Substrate Selection Hypothesis in Neurodegenerative Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 22
PMID 33477465
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A number of neurodegenerative diseases including prion diseases, tauopathies and synucleinopathies exhibit multiple clinical phenotypes. A diversity of clinical phenotypes has been attributed to the ability of amyloidogenic proteins associated with a particular disease to acquire multiple, conformationally distinct, self-replicating states referred to as strains. Structural diversity of strains formed by tau, α-synuclein or prion proteins has been well documented. However, the question how different strains formed by the same protein elicit different clinical phenotypes remains poorly understood. The current article reviews emerging evidence suggesting that posttranslational modifications are important players in defining strain-specific structures and disease phenotypes. This article put forward a new hypothesis referred to as substrate selection hypothesis, according to which individual strains selectively recruit protein isoforms with a subset of posttranslational modifications that fit into strain-specific structures. Moreover, it is proposed that as a result of selective recruitment, strain-specific patterns of posttranslational modifications are formed, giving rise to unique disease phenotypes. Future studies should define whether cell-, region- and age-specific differences in metabolism of posttranslational modifications play a causative role in dictating strain identity and structural diversity of strains of sporadic origin.

Citing Articles

Investigation of All Disease-Relevant Lysine Acetylation Sites in α-Synuclein Enabled by Non-canonical Amino Acid Mutagenesis.

Shimogawa M, Li M, Park G, Ramirez J, Lee H, Watson P bioRxiv. 2025; .

PMID: 39896484 PMC: 11785115. DOI: 10.1101/2025.01.21.634178.


Structural Variations of Prions and Prion-like Proteins Associated with Neurodegeneration.

Christensen C, Wang S, Li W, Yu D, Li H Curr Issues Mol Biol. 2024; 46(7):6423-6439.

PMID: 39057026 PMC: 11275340. DOI: 10.3390/cimb46070384.


Orthogonal Translation for Site-Specific Installation of Post-translational Modifications.

Gan Q, Fan C Chem Rev. 2024; 124(5):2805-2838.

PMID: 38373737 PMC: 11230630. DOI: 10.1021/acs.chemrev.3c00850.


AI and protein structure and function in neurological disease: relevance to disease management.

Outeiro T, Vieira T Nat Rev Neurol. 2023; 19(8):453-454.

PMID: 37394622 DOI: 10.1038/s41582-023-00840-z.


New developments in prion disease research.

Gilch S, Schatzl H Cell Tissue Res. 2023; 392(1):1-5.

PMID: 36918429 DOI: 10.1007/s00441-023-03760-y.


References
1.
Lee V, Goedert M, Trojanowski J . Neurodegenerative tauopathies. Annu Rev Neurosci. 2001; 24:1121-59. DOI: 10.1146/annurev.neuro.24.1.1121. View

2.
Makarava N, Savtchenko R, Baskakov I . Two alternative pathways for generating transmissible prion disease de novo. Acta Neuropathol Commun. 2015; 3:69. PMC: 4641408. DOI: 10.1186/s40478-015-0248-5. View

3.
Jucker M, Walker L . Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013; 501(7465):45-51. PMC: 3963807. DOI: 10.1038/nature12481. View

4.
Srivastava S, Katorcha E, Daus M, Lasch P, Beekes M, Baskakov I . Sialylation Controls Prion Fate . J Biol Chem. 2016; 292(6):2359-2368. PMC: 5313106. DOI: 10.1074/jbc.M116.768010. View

5.
Turk E, Teplow D, HOOD L, Prusiner S . Purification and properties of the cellular and scrapie hamster prion proteins. Eur J Biochem. 1988; 176(1):21-30. DOI: 10.1111/j.1432-1033.1988.tb14246.x. View